[Korea Biomedical Review]

Genencell applies for late-stage clinical trials of plant-extracted Covid-19 therapy

Genencell said Tuesday that it asked the Ministry of Food and Drug Safety to authorize phase 2 and 3 clinical trials of ES16001, the company’s oral Covid-19 therapy.
The company expects the domestic study to serve as a starting point for its global clinical trials of ES16001 in European countries.

http://www.koreabiomed.com/news/articleView.html?idxno=12325